{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T05:45:37Z","timestamp":1785735937748,"version":"3.56.0"},"reference-count":281,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Heart failure (HF) with preserved ejection fraction (HFpEF) is a heterogeneous syndrome encompassing hypertensive left ventricular remodelling with diastolic dysfunction and systemic inflammation-driven endothelial dysfunction, with possible contributions from visceral adipose tissue-associated metabolic and proinflammatory alterations. However, conventional key risk factors for HFpEF, including advanced age, female sex, obesity, diabetes, and chronic kidney disease, are closely associated with mineralocorticoid receptor (MR) overactivation through several under-recognized mechanisms, i.e. renin-independent aldosterone excess, cortisol dysregulation, and ligand-independent activation. MR overactivation promotes myocardial hypertrophy and fibrosis, vascular remodelling, and systemic inflammation, all of which are hallmark features of HFpEF. Among patients with HFpEF, the steroidal MR antagonist (MRA) spironolactone has been suggested to reduce the risk of HF-related events, while the non-steroidal MRA finerenone has significantly reduced the primary composite of total worsening HF events and cardiovascular death. Across subgroups suggestive of MR overactivation, MRA therapy has shown generally consistent efficacy and safety, although greater adiposity may be associated with greater MRA efficacy. Given the continuum of MR activation across HF stages, early therapeutic intervention targeting MR overactivation may mitigate the risk of HFpEF development and progression. Furthermore, aldosterone synthase inhibitors and MR modulators, which also attenuate MR overactivation, are being evaluated for HFpEF prevention and treatment. This paper presents the mechanistic pathways linking MR overactivation to HFpEF and highlights the potential benefits of mitigating MR activation for its prevention and treatment, calling for renewed consideration of treatment strategies in clinical practice and trial design.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehag578","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T11:51:24Z","timestamp":1783770684000},"source":"Crossref","is-referenced-by-count":0,"title":["Mineralocorticoid receptor overactivation in heart failure with preserved ejection fraction"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0008-2256","authenticated-orcid":false,"given":"Masatake","family":"Kobayashi","sequence":"first","affiliation":[{"name":"Department of Cardiology, Tokyo Medical University , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5880-275X","authenticated-orcid":false,"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Michigan , Ann Arbor, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-1570","authenticated-orcid":false,"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"CHRU de Nancy, Centre d'Investigations Cliniques Plurith\u00e9matique 1433, INSERM, Universit\u00e9 de Lorraine, INSERM U1116 - DCAC, and F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists) , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"2026080301192479700_ehag578-B1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.cardfail.2024.07.001","article-title":"HF STATS 2024: heart failure epidemiology and outcomes statistics an updated 2024 report from the Heart Failure Society of America","volume":"31","author":"Bozkurt","year":"2025","journal-title":"J Card Fail"},{"key":"2026080301192479700_ehag578-B2","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","article-title":"Epidemiology of heart failure with preserved ejection fraction","volume":"14","author":"Dunlay","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"2026080301192479700_ehag578-B3","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.cardfail.2025.07.007","article-title":"HF STATS 2025: heart failure epidemiology and outcomes statistics an updated 2025 report from the Heart Failure Society of America","volume":"32","author":"Writing Committee Members","year":"2025","journal-title":"J Card Fail"},{"key":"2026080301192479700_ehag578-B4","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","article-title":"Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes","volume":"70","author":"Shah","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026080301192479700_ehag578-B5","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1161\/CIRCOUTCOMES.110.957571","article-title":"Population impact of heart failure and the most common forms of cancer: a study of 1 162 309 hospital cases in Sweden (1988 to 2004)","volume":"3","author":"Stewart","year":"2010","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026080301192479700_ehag578-B6","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1056\/NEJMoa032566","article-title":"Diastolic heart failure\u2013abnormalities in active relaxation and passive stiffness of the left ventricle","volume":"350","author":"Zile","year":"2004","journal-title":"N Engl J Med"},{"key":"2026080301192479700_ehag578-B7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026080301192479700_ehag578-B8","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.jacc.2025.06.055","article-title":"The adipokine hypothesis of heart failure with a preserved ejection fraction: a novel framework to explain pathogenesis and guide treatment","volume":"86","author":"Packer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026080301192479700_ehag578-B9","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jacc.2025.09.005","article-title":"The adipokine hypothesis of HFpEF: a bold unifying framework in need of translational proof","volume":"86","author":"Zannad","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026080301192479700_ehag578-B10","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.cardfail.2022.09.018","article-title":"Epidemiology, pathophysiology, diagnosis, and therapy of heart failure with preserved ejection fraction in Japan","volume":"29","author":"Obokata","year":"2023","journal-title":"J Card Fail"},{"key":"2026080301192479700_ehag578-B11","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","article-title":"Heart failure with preserved ejection fraction: JACC scientific statement","volume":"81","author":"Borlaug","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026080301192479700_ehag578-B12","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1002\/ejhf.2894","article-title":"Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension","volume":"25","author":"Anker","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026080301192479700_ehag578-B13","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1056\/NEJMcp2305181","article-title":"Heart failure with preserved ejection fraction","volume":"392","author":"Cannata","year":"2025","journal-title":"N Engl J Med"},{"key":"2026080301192479700_ehag578-B14","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrcardio.2014.83","article-title":"The pathophysiology of heart failure with preserved ejection fraction","volume":"11","author":"Borlaug","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"2026080301192479700_ehag578-B15","doi-asserted-by":"publisher","first-page":"e466","DOI":"10.1161\/CIRCULATIONAHA.111.067918","article-title":"Aldosterone, mineralocorticoid receptor activation, and cardiovascular remodeling","volume":"124","author":"Leopold","year":"2011","journal-title":"Circulation"},{"key":"2026080301192479700_ehag578-B16","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1161\/HYPERTENSIONAHA.122.17964","article-title":"Aldosterone as a mediator of cardiovascular damage","volume":"79","author":"Buffolo","year":"2022","journal-title":"Hypertension"},{"key":"2026080301192479700_ehag578-B17","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"2026080301192479700_ehag578-B18","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s11427-021-1945-6","article-title":"Aldosterone dysregulation predicts the risk of mortality and rehospitalization in heart failure with a preserved ejection fraction","volume":"65","author":"Ke","year":"2022","journal-title":"Sci China Life Sci"},{"key":"2026080301192479700_ehag578-B19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ijcard.2019.08.040","article-title":"Sympathetic and renin-angiotensin-aldosterone system activation in heart failure with preserved, mid-range and reduced ejection fraction","volume":"296","author":"Vergaro","year":"2019","journal-title":"Int J Cardiol"},{"key":"2026080301192479700_ehag578-B20","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1161\/CIRCRESAHA.116.303604","article-title":"The sympathetic nervous system alterations in human hypertension","volume":"116","author":"Grassi","year":"2015","journal-title":"Circ Res"},{"key":"2026080301192479700_ehag578-B21","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2026080301192479700_ehag578-B22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"2026080301192479700_ehag578-B23","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1093\/eurheartj\/ehac299","article-title":"Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease","volume":"43","author":"Pandey","year":"2022","journal-title":"Eur Heart J"},{"key":"2026080301192479700_ehag578-B24","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.3390\/ijms18051032","article-title":"Aldosterone and mineralocorticoid receptors-physiology and pathophysiology","volume":"18","author":"Funder","year":"2017","journal-title":"Int J Mol Sci"},{"key":"2026080301192479700_ehag578-B25","doi-asserted-by":"publisher","first-page":"F181","DOI":"10.1152\/ajprenal.2001.280.2.F181","article-title":"Multiple aspects of mineralocorticoid selectivity","volume":"280","author":"Farman","year":"2001","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026080301192479700_ehag578-B26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1146\/annurev-physiol-042022-015223","article-title":"The mineralocorticoid receptor in the vasculature: friend or foe?","volume":"86","author":"Ibarrola","year":"2024","journal-title":"Annu Rev Physiol"},{"key":"2026080301192479700_ehag578-B27","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1016\/j.jacc.2026.02.5090","article-title":"Redefining primary aldosteronism","volume":"87","author":"Vaidya","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"2026080301192479700_ehag578-B28","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.jchf.2018.01.009","article-title":"Obesity-related heart failure with a preserved ejection fraction: the mechanistic rationale for combining inhibitors of aldosterone, neprilysin, and sodium-glucose cotransporter-2","volume":"6","author":"Packer","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2026080301192479700_ehag578-B29","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1172\/JCI43124","article-title":"Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway","volume":"121","author":"Shibata","year":"2011","journal-title":"J Clin Invest"},{"key":"2026080301192479700_ehag578-B30","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1097\/HJH.0b013e3283576904","article-title":"Mineralocorticoid receptor\u2013Rac1 activation and oxidative stress play major roles in salt-induced hypertension and kidney injury in prepubertal rats","volume":"30","author":"Kawarazaki","year":"2012","journal-title":"J Hypertens"},{"key":"2026080301192479700_ehag578-B31","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.jacc.2019.05.052","article-title":"Age-related characteristics and outcomes of patients with heart failure with preserved ejection fraction","volume":"74","author":"Tromp","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026080301192479700_ehag578-B32","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S0140-6736(23)02756-3","article-title":"Heart failure with preserved ejection fraction: everything the clinician needs to know","volume":"403","author":"Campbell","year":"2024","journal-title":"Lancet (London, England)"},{"key":"2026080301192479700_ehag578-B33","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2147\/CLEP.S253612","article-title":"Risk factors for heart failure with preserved or reduced ejection fraction among Medicare beneficiaries: application of competing risks analysis and gradient boosted model","volume":"12","author":"Lee","year":"2020","journal-title":"Clin Epidemiol"},{"key":"2026080301192479700_ehag578-B34","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1161\/CIRCULATIONAHA.117.028201","article-title":"Age-related autonomous aldosteronism","volume":"136","author":"Nanba","year":"2017","journal-title":"Circulation"},{"key":"2026080301192479700_ehag578-B35","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1093\/ajh\/hps080","article-title":"Age-related changes in 11\u03b2-hydroxysteroid dehydrogenase type 2 activity in normotensive subjects","volume":"26","author":"Campino","year":"2013","journal-title":"Am J Hypertens"},{"key":"2026080301192479700_ehag578-B36","doi-asserted-by":"publisher","first-page":"e88942","DOI":"10.1172\/jci.insight.88942","article-title":"Vascular mineralocorticoid receptor regulates microRNA-155 to promote vasoconstriction and rising blood pressure with aging","volume":"1","author":"DuPont","year":"2016","journal-title":"JCI Insight"},{"key":"2026080301192479700_ehag578-B37","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1161\/HYPERTENSIONAHA.111.185520","article-title":"Oxidative stress causes mineralocorticoid receptor activation in rat cardiomyocytes: role of small GTPase Rac1","volume":"59","author":"Nagase","year":"2012","journal-title":"Hypertension"},{"key":"2026080301192479700_ehag578-B38","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1161\/CIRCULATIONAHA.117.031622","article-title":"Sex and race differences in lifetime risk of heart failure with preserved ejection fraction and heart failure with reduced ejection fraction","volume":"137","author":"Pandey","year":"2018","journal-title":"Circulation"},{"key":"2026080301192479700_ehag578-B39","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2026080301192479700_ehag578-B40","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"key":"2026080301192479700_ehag578-B41","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026080301192479700_ehag578-B42","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026080301192479700_ehag578-B43","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"2026080301192479700_ehag578-B44","doi-asserted-by":"publisher","first-page":"e007675","DOI":"10.1161\/JAHA.117.007675","article-title":"Sex-specific mechanisms of resistance vessel endothelial dysfunction induced by cardiometabolic risk factors","volume":"7","author":"Davel","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2026080301192479700_ehag578-B45","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1161\/HYPERTENSIONAHA.116.07660","article-title":"Estrogen signaling in the adrenal cortex: implications for blood pressure sex differences","volume":"68","author":"Caroccia","year":"2016","journal-title":"Hypertension"},{"key":"2026080301192479700_ehag578-B46","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.crphys.2021.03.003","article-title":"Signalling mechanisms in the cardiovascular protective effects of estrogen: with a focus on rapid\/membrane signalling","volume":"4","author":"Ni\u021b\u0103","year":"2021","journal-title":"Curr Res Physiol"},{"key":"2026080301192479700_ehag578-B47","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1161\/HYPERTENSIONAHA.117.11087","article-title":"Biological sex modulates the adrenal and blood pressure responses to angiotensin II","volume":"71","author":"Shukri","year":"2018","journal-title":"Hypertension"},{"key":"2026080301192479700_ehag578-B48","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1210\/jc.2017-00957","article-title":"The association of estrogen receptor-\u03b2 gene variation with salt-sensitive blood pressure","volume":"102","author":"Manosroi","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2026080301192479700_ehag578-B49","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jacc.2016.05.019","article-title":"The HFpEF obesity phenotype: the elephant in the room","volume":"68","author":"Kitzman","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026080301192479700_ehag578-B50","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"2026080301192479700_ehag578-B51","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jchf.2018.07.009","article-title":"Adiposity and incident heart failure and its subtypes: MESA (Multi-Ethnic Study of Atherosclerosis)","volume":"6","author":"Rao","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2026080301192479700_ehag578-B52","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/ejhf.1956","article-title":"Regional adiposity and heart failure with preserved ejection fraction","volume":"22","author":"Rao","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026080301192479700_ehag578-B53","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1093\/eurheartj\/ehaf057","article-title":"Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial","volume":"46","author":"Peikert","year":"2025","journal-title":"Eur Heart J"},{"key":"2026080301192479700_ehag578-B54","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1002\/ejhf.2741","article-title":"Connecting epicardial adipose tissue and heart failure with preserved ejection fraction: mechanisms, management and modern perspectives","volume":"24","author":"van Woerden","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026080301192479700_ehag578-B55","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1016\/j.jacc.2021.04.003","article-title":"Pericardial fat and the risk of heart failure","volume":"77","author":"Kenchaiah","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026080301192479700_ehag578-B56","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1161\/HYPERTENSIONAHA.114.04981","article-title":"Adipocyte mineralocorticoid receptor activation leads to metabolic syndrome and induction of prostaglandin D2 synthase","volume":"66","author":"Urbanet","year":"2015","journal-title":"Hypertension"},{"key":"2026080301192479700_ehag578-B57","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.190223","article-title":"Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction","volume":"59","author":"Briones","year":"2012","journal-title":"Hypertension"},{"key":"2026080301192479700_ehag578-B58","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1161\/CIRCULATIONAHA.117.032474","article-title":"Leptin-aldosterone-neprilysin axis: identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity","volume":"137","author":"Packer","year":"2018","journal-title":"Circulation"},{"key":"2026080301192479700_ehag578-B59","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1161\/CIRCULATIONAHA.115.018226","article-title":"Adipocyte-derived hormone leptin is a direct regulator of aldosterone secretion, which promotes endothelial dysfunction and cardiac fibrosis","volume":"132","author":"Huby","year":"2015","journal-title":"Circulation"},{"key":"2026080301192479700_ehag578-B60","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/MNH.0000000000000384","article-title":"The regulation of aldosterone secretion by leptin: implications in obesity-related cardiovascular disease","volume":"27","author":"Faulkner","year":"2018","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2026080301192479700_ehag578-B61","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.mce.2011.09.011","article-title":"The role of the mineralocorticoid receptor in adipocyte biology and fat metabolism","volume":"350","author":"Marzolla","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"2026080301192479700_ehag578-B62","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.cellsig.2017.08.004","article-title":"In situ detection of the activation of Rac1 and RalA small GTPases in mouse adipocytes by immunofluorescent microscopy following in vivo and ex vivo insulin stimulation","volume":"39","author":"Takenaka","year":"2017","journal-title":"Cell Signal"},{"key":"2026080301192479700_ehag578-B63","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/nm.1879","article-title":"Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease","volume":"14","author":"Shibata","year":"2008","journal-title":"Nat Med"},{"key":"2026080301192479700_ehag578-B64","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1677\/jme.1.01718","article-title":"Hexose-6-phosphate dehydrogenase confers oxo-reductase activity upon 11 beta-hydroxysteroid dehydrogenase type 1","volume":"34","author":"Bujalska","year":"2005","journal-title":"J Mol Endocrinol"},{"key":"2026080301192479700_ehag578-B65","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1007\/s11883-013-0320-1","article-title":"Modulation of 11\u03b2-hydroxysteroid dehydrogenase as a strategy to reduce vascular inflammation","volume":"15","author":"Hadoke","year":"2013","journal-title":"Curr Atheroscler Rep"},{"key":"2026080301192479700_ehag578-B66","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.amjcard.2018.04.052","article-title":"Relation of obstructive sleep apnea to risk of hospitalization in patients with heart failure and preserved ejection fraction from the national inpatient sample","volume":"122","author":"Abdullah","year":"2018","journal-title":"Am J Cardiol"},{"key":"2026080301192479700_ehag578-B67","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.109.901801","article-title":"Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study","volume":"122","author":"Gottlieb","year":"2010","journal-title":"Circulation"},{"key":"2026080301192479700_ehag578-B68","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1093\/eurjhf\/hfp057","article-title":"Sleep-disordered breathing in heart failure with normal left ventricular ejection fraction","volume":"11","author":"Bitter","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"2026080301192479700_ehag578-B69","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.cardfail.2011.01.013","article-title":"High prevalence of sleep apnea in heart failure outpatients: even in patients with preserved systolic function","volume":"17","author":"Herrscher","year":"2011","journal-title":"J Card Fail"},{"key":"2026080301192479700_ehag578-B70","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11906-018-0819-5","article-title":"Role of mineralocorticoid receptors in obstructive sleep apnea and metabolic syndrome","volume":"20","author":"Valaiyapathi","year":"2018","journal-title":"Curr Hypertens Rep"},{"key":"2026080301192479700_ehag578-B71","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1161\/CIR.0000000000000988","article-title":"Obstructive sleep apnea and cardiovascular disease: a scientific statement from the American Heart Association","volume":"144","author":"Yeghiazarians","year":"2021","journal-title":"Circulation"},{"key":"2026080301192479700_ehag578-B72","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1161\/HYPERTENSIONAHA.119.13833","article-title":"Primary aldosteronism and obstructive sleep apnea: a cross-sectional multi-ethnic study","volume":"74","author":"Buffolo","year":"2019","journal-title":"Hypertension"},{"key":"2026080301192479700_ehag578-B73","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1097\/HJH.0000000000001254","article-title":"Effects of continuous positive airway pressure treatment on aldosterone excretion in patients with obstructive sleep apnoea and resistant hypertension: a randomized controlled trial","volume":"35","author":"de Souza","year":"2017","journal-title":"J Hypertens"},{"key":"2026080301192479700_ehag578-B74","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/jhh.2009.96","article-title":"Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report","volume":"24","author":"Gaddam","year":"2010","journal-title":"J Hum Hypertens"},{"key":"2026080301192479700_ehag578-B75","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/ejhf.813","article-title":"Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry","volume":"19","author":"Chioncel","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026080301192479700_ehag578-B76","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/ejhf.2408","article-title":"A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction\u2014insights from the ESC-HFA EORP Heart Failure Long-Term Registry","volume":"24","author":"Kap\u0142on-Cie\u015blicka","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026080301192479700_ehag578-B77","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/j.cardfail.2021.04.015","article-title":"Association between \u03b2-blockers and outcomes in heart failure with preserved ejection fraction: current insights from the SwedeHF registry","volume":"27","author":"Meyer","year":"2021","journal-title":"J Card Fail"},{"key":"2026080301192479700_ehag578-B78","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ahj.2016.07.025","article-title":"Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: findings from Get With The Guidelines-Heart Failure registry","volume":"182","author":"Echouffo-Tcheugui","year":"2016","journal-title":"Am Heart J"},{"key":"2026080301192479700_ehag578-B79","doi-asserted-by":"publisher","first-page":"e007901","DOI":"10.1161\/CIRCHEARTFAILURE.120.007901","article-title":"Global differences in heart failure with preserved ejection fraction: the PARAGON-HF trial","volume":"14","author":"Tromp","year":"2021","journal-title":"Circ Heart Fail"},{"key":"2026080301192479700_ehag578-B80","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jchf.2016.09.015","article-title":"Prevalence and clinical significance of diabetes in Asian versus white patients with heart failure","volume":"5","author":"Bank","year":"2017","journal-title":"JACC Heart Fail"},{"key":"2026080301192479700_ehag578-B81","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1002\/ehf2.13302","article-title":"Prognostic significance of the HFA-PEFF score in patients with heart failure with preserved ejection fraction","volume":"8","author":"Sotomi","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026080301192479700_ehag578-B82","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026080301192479700_ehag578-B83","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026080301192479700_ehag578-B84","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1161\/CIRCULATIONAHA.121.055830","article-title":"Diabetes status modifies the association between different measures of obesity and heart failure risk among older adults: a pooled analysis of community-based NHLBI cohorts","volume":"145","author":"Patel","year":"2022","journal-title":"Circulation"},{"key":"2026080301192479700_ehag578-B85","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1016\/j.jacc.2025.07.052","article-title":"Is type 2 diabetes a modifiable risk factor for the evolution and progression of heart failure with a preserved ejection fraction?","volume":"86","author":"Packer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026080301192479700_ehag578-B86","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1002\/ejhf.3347","article-title":"Diabetic myocardial disorder. A clinical consensus statement of the Heart Failure Association of the ESC and the ESC Working Group on myocardial & pericardial diseases","volume":"26","author":"Seferovi\u0107","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026080301192479700_ehag578-B87","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.1210\/en.2006-0944","article-title":"Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus","volume":"147","author":"Guo","year":"2006","journal-title":"Endocrinology"},{"key":"2026080301192479700_ehag578-B88","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1210\/en.2003-1137","article-title":"Rapid, nongenomic effects of aldosterone in the heart mediated by epsilon protein kinase C","volume":"145","author":"Mihailidou","year":"2004","journal-title":"Endocrinology"},{"key":"2026080301192479700_ehag578-B89","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.2337\/dc07-0525","article-title":"Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients","volume":"30","author":"Colussi","year":"2007","journal-title":"Diabetes Care"},{"key":"2026080301192479700_ehag578-B90","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.2337\/diabetes.49.11.1751","article-title":"Triggering and amplifying pathways of regulation of insulin secretion by glucose","volume":"49","author":"Henquin","year":"2000","journal-title":"Diabetes"},{"key":"2026080301192479700_ehag578-B91","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1055\/s-2005-870240","article-title":"Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes","volume":"37","author":"Kraus","year":"2005","journal-title":"Horm Metab Res"},{"key":"2026080301192479700_ehag578-B92","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1161\/01.HYP.15.6.861","article-title":"Hyperinsulinemia and the aldosterone and pressor responses to angiotensin II","volume":"15","author":"Rocchini","year":"1990","journal-title":"Hypertension"},{"key":"2026080301192479700_ehag578-B93","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S2213-8587(24)00309-7","article-title":"Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial","volume":"13","author":"Butt","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026080301192479700_ehag578-B94","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1097\/HJH.0000000000002910","article-title":"Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension","volume":"39","author":"Kasiakogias","year":"2021","journal-title":"J Hypertens"},{"key":"2026080301192479700_ehag578-B95","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1161\/CIRCULATIONAHA.110.954388","article-title":"Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum","volume":"123","author":"Borlaug","year":"2011","journal-title":"Circulation"},{"key":"2026080301192479700_ehag578-B96","doi-asserted-by":"publisher","first-page":"e002883","DOI":"10.1161\/CIRCHEARTFAILURE.115.002883","article-title":"Risk factors for incident hospitalized heart failure with preserved versus reduced ejection fraction in a multiracial cohort of postmenopausal women","volume":"9","author":"Eaton","year":"2016","journal-title":"Circ Heart Fail"},{"key":"2026080301192479700_ehag578-B97","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1161\/01.CIR.0000039105.49749.6F","article-title":"Lifetime risk for developing congestive heart failure: the fFramingham Heart Study","volume":"106","author":"Lloyd-Jones","year":"2002","journal-title":"Circulation"},{"key":"2026080301192479700_ehag578-B98","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jchf.2022.04.006","article-title":"Apparent treatment-resistant hypertension across the Spectrum of heart failure phenotypes in the Swedish HF registry","volume":"10","author":"Jackson","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2026080301192479700_ehag578-B99","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrneph.2010.30","article-title":"Aldosterone: effects on the kidney and cardiovascular system","volume":"6","author":"Briet","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"2026080301192479700_ehag578-B100","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/00004872-200018030-00001","article-title":"The role of the 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension","volume":"18","author":"Ferrari","year":"2000","journal-title":"J Hypertens"},{"key":"2026080301192479700_ehag578-B101","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1161\/HYPERTENSIONAHA.124.23385","article-title":"Update on low-renin hypertension: current understanding and future direction","volume":"81","author":"Shah","year":"2024","journal-title":"Hypertension"},{"key":"2026080301192479700_ehag578-B102","doi-asserted-by":"publisher","first-page":"101526","DOI":"10.1016\/j.jacbts.2026.101526","article-title":"Unmasking hormonal mechanisms of hypertension in obesity","volume":"11","author":"Parisien-La Salle","year":"2026","journal-title":"JACC Basic Transl Sci"},{"key":"2026080301192479700_ehag578-B103","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7326\/M20-0065","article-title":"The unrecognized prevalence of primary aldosteronism: a cross-sectional study","volume":"173","author":"Brown","year":"2020","journal-title":"Ann Intern Med"},{"key":"2026080301192479700_ehag578-B104","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026080301192479700_ehag578-B105","doi-asserted-by":"publisher","first-page":"289","DOI":"10.7326\/M20-4873","article-title":"Testing for primary aldosteronism and mineralocorticoid receptor antagonist use among U.S. veterans: a retrospective cohort study","volume":"174","author":"Cohen","year":"2021","journal-title":"Ann Intern Med"},{"key":"2026080301192479700_ehag578-B106","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1161\/01.HYP.27.5.1039","article-title":"Changes in left ventricular anatomy and function in hypertension and primary aldosteronism","volume":"27","author":"Rossi","year":"1996","journal-title":"Hypertension"},{"key":"2026080301192479700_ehag578-B107","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1016\/j.jcmg.2020.06.026","article-title":"Aldosterone-related myocardial extracellular matrix expansion in hypertension in humans: a proof-of-concept study by cardiac magnetic resonance","volume":"13","author":"Redheuil","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026080301192479700_ehag578-B108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2019.01.006","article-title":"Long-term outcomes for heart failure patients with and without diabetes: from the Get With The Guidelines-Heart Failure Registry","volume":"211","author":"Ziaeian","year":"2019","journal-title":"Am Heart J"},{"key":"2026080301192479700_ehag578-B109","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41569-021-00605-5","article-title":"Heart failure with mid-range or mildly reduced ejection fraction","volume":"19","author":"Savarese","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"2026080301192479700_ehag578-B110","doi-asserted-by":"publisher","first-page":"e021660","DOI":"10.1161\/JAHA.121.021660","article-title":"Coronary artery disease and heart failure with preserved ejection fraction: the ARIC study","volume":"11","author":"John","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2026080301192479700_ehag578-B111","doi-asserted-by":"publisher","first-page":"4f","DOI":"10.1016\/j.amjcard.2006.03.004","article-title":"Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiology","volume":"97","author":"Cohn","year":"2006","journal-title":"Am J Cardiol"},{"key":"2026080301192479700_ehag578-B112","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1161\/01.CIR.99.20.2694","article-title":"Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis","volume":"99","author":"Silvestre","year":"1999","journal-title":"Circulation"},{"key":"2026080301192479700_ehag578-B113","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1161\/01.CIR.0000163562.82134.8E","article-title":"Persistent cardiac aldosterone synthesis in angiotensin II type 1A receptor-knockout mice after myocardial infarction","volume":"111","author":"Katada","year":"2005","journal-title":"Circulation"},{"key":"2026080301192479700_ehag578-B114","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1161\/HYPERTENSIONAHA.117.09791","article-title":"Aldosterone target NGAL (neutrophil gelatinase-associated lipocalin) is involved in cardiac remodeling after myocardial infarction through NF\u03baB pathway","volume":"70","author":"Mart\u00ednez-Mart\u00ednez","year":"2017","journal-title":"Hypertension"},{"key":"2026080301192479700_ehag578-B115","doi-asserted-by":"publisher","first-page":"5049","DOI":"10.1093\/eurheartj\/ehad592","article-title":"Prevalence and incidence of diastolic dysfunction in atrial fibrillation: clinical implications","volume":"44","author":"Naser","year":"2023","journal-title":"Eur Heart J"},{"key":"2026080301192479700_ehag578-B116","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/ejhf.3402","article-title":"Characterizing atrial fibrillation in patients with and without heart failure across the ejection fraction spectrum: incidence, prevalence, and treatment strategies","volume":"27","author":"Valente","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026080301192479700_ehag578-B117","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1161\/CIRCULATIONAHA.115.018614","article-title":"Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction","volume":"133","author":"Santhanakrishnan","year":"2016","journal-title":"Circulation"},{"key":"2026080301192479700_ehag578-B118","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.jacc.2015.06.1314","article-title":"Incidence of atrial fibrillation and relationship with cardiovascular events, heart failure, and mortality: a community-based study from The Netherlands","volume":"66","author":"Vermond","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026080301192479700_ehag578-B119","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1093\/eurheartj\/ehad811","article-title":"Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis of clinical trials","volume":"45","author":"Oraii","year":"2024","journal-title":"Eur Heart J"},{"key":"2026080301192479700_ehag578-B120","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/j.jacc.2025.03.429","article-title":"Finerenone reduces new-onset atrial fibrillation across the Spectrum of cardio-kidney-metabolic syndrome: the FINE-HEART pooled analysis","volume":"85","author":"Pabon","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026080301192479700_ehag578-B121","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1093\/eurheartj\/ehr266","article-title":"Aldosterone promotes atrial fibrillation","volume":"33","author":"Reil","year":"2012","journal-title":"Eur Heart J"},{"key":"2026080301192479700_ehag578-B122","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/clc.20689","article-title":"Increased expression of mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase type 2 in human atria during atrial fibrillation","volume":"33","author":"De-An","year":"2010","journal-title":"Clin Cardiol"},{"key":"2026080301192479700_ehag578-B123","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.bcp.2019.07.001","article-title":"The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling","volume":"168","author":"Lavall","year":"2019","journal-title":"Biochem Pharmacol"},{"key":"2026080301192479700_ehag578-B124","doi-asserted-by":"publisher","first-page":"7542","DOI":"10.1074\/jbc.M116.764449","article-title":"Rac1 GTPase regulates 11\u03b2 hydroxysteroid dehydrogenase type 2 and fibrotic remodeling","volume":"292","author":"Lavall","year":"2017","journal-title":"J Biol Chem"},{"key":"2026080301192479700_ehag578-B125","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1016\/j.jacc.2019.09.063","article-title":"Echocardiographic features of patients with heart failure and preserved left ventricular ejection fraction","volume":"74","author":"Shah","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026080301192479700_ehag578-B126","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1161\/CIRCHEARTFAILURE.114.001583","article-title":"Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial","volume":"7","author":"Shah","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2026080301192479700_ehag578-B127","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.jacc.2020.06.069","article-title":"Pulmonary hypertension in HFpEF and HFrEF: JACC review topic of the week","volume":"76","author":"Guazzi","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026080301192479700_ehag578-B128","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1161\/HYPERTENSIONAHA.122.19207","article-title":"Mineralocorticoid receptor antagonism by finerenone attenuates established pulmonary hypertension in rats","volume":"79","author":"Tu","year":"2022","journal-title":"Hypertension"},{"key":"2026080301192479700_ehag578-B129","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1161\/CIRCULATIONAHA.112.094722","article-title":"Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension","volume":"126","author":"Maron","year":"2012","journal-title":"Circulation"},{"key":"2026080301192479700_ehag578-B130","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1111\/bph.15805","article-title":"Smooth muscle Rac1 contributes to pulmonary hypertension","volume":"179","author":"Dilasser","year":"2022","journal-title":"Br J Pharmacol"},{"key":"2026080301192479700_ehag578-B131","doi-asserted-by":"publisher","first-page":"4893","DOI":"10.1002\/ehf2.13429","article-title":"Risk factors and prediction models for incident heart failure with reduced and preserved ejection fraction","volume":"8","author":"Gaziano","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026080301192479700_ehag578-B132","doi-asserted-by":"publisher","first-page":"e021494","DOI":"10.1161\/JAHA.121.021494","article-title":"Impact of chronic obstructive pulmonary disease in patients with heart failure with preserved ejection fraction: insights from PARAGON-HF","volume":"10","author":"Mooney","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026080301192479700_ehag578-B133","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1002\/ejhf.1593","article-title":"Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial","volume":"22","author":"Ramalho","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026080301192479700_ehag578-B134","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1161\/CIRCHEARTFAILURE.109.932996","article-title":"Factors associated with outcome in heart failure with preserved ejection fraction: findings from the irbesartan in heart failure with preserved ejection fraction study (I-PRESERVE)","volume":"4","author":"Komajda","year":"2011","journal-title":"Circ Heart Fail"},{"key":"2026080301192479700_ehag578-B135","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.cardiores.2003.11.037","article-title":"Review of aldosterone- and angiotensin II-induced target organ damage and prevention","volume":"61","author":"Struthers","year":"2004","journal-title":"Cardiovasc Res"},{"key":"2026080301192479700_ehag578-B136","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/eurheartj\/ehi023","article-title":"Spironolactone improves lung diffusion in chronic heart failure","volume":"26","author":"Agostoni","year":"2005","journal-title":"Eur Heart J"},{"key":"2026080301192479700_ehag578-B137","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1161\/CIRCULATIONAHA.113.007690","article-title":"Upregulation of steroidogenic acute regulatory protein by hypoxia stimulates aldosterone synthesis in pulmonary artery endothelial cells to promote pulmonary vascular fibrosis","volume":"130","author":"Maron","year":"2014","journal-title":"Circulation"},{"key":"2026080301192479700_ehag578-B138","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.hrtlng.2024.04.007","article-title":"Causal relationship between chronic obstructive pulmonary disease and heart failure: a Mendelian randomization study","volume":"67","author":"Jiang","year":"2024","journal-title":"Heart Lung"},{"key":"2026080301192479700_ehag578-B139","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1002\/ejhf.821","article-title":"Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction","volume":"19","author":"L\u00f6fman","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026080301192479700_ehag578-B140","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jacc.2021.05.002","article-title":"Kidney function and outcomes in patients hospitalized with heart failure","volume":"78","author":"Patel","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026080301192479700_ehag578-B141","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jchf.2023.01.029","article-title":"Chronic kidney disease, heart failure, and adverse cardiac remodeling in older adults: the ARIC study","volume":"11","author":"Buckley","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026080301192479700_ehag578-B142","doi-asserted-by":"publisher","first-page":"e011173","DOI":"10.1161\/CIRCHEARTFAILURE.123.011173","article-title":"Risk factors and outcomes associated with heart failure with preserved and reduced ejection fraction in people with chronic kidney disease","volume":"17","author":"Bansal","year":"2024","journal-title":"Circ Heart Fail"},{"key":"2026080301192479700_ehag578-B143","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1093\/eurheartj\/eht066","article-title":"Incidence and epidemiology of new onset heart failure with preserved vs. Reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND","volume":"34","author":"Brouwers","year":"2013","journal-title":"Eur Heart J"},{"key":"2026080301192479700_ehag578-B144","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1001\/jamacardio.2017.4987","article-title":"Association of cardiovascular biomarkers with incident heart failure with preserved and reduced ejection fraction","volume":"3","author":"de Boer","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2026080301192479700_ehag578-B145","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/ndt\/gfae004","article-title":"When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases","volume":"39","author":"Kobayashi","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2026080301192479700_ehag578-B146","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/j.jacc.2025.03.009","article-title":"Interplay of chronic kidney disease and the effects of tirzepatide in patients with heart failure, preserved ejection fraction, and obesity: the SUMMIT trial","volume":"85","author":"Packer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026080301192479700_ehag578-B147","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1038\/s41591-024-03264-4","article-title":"Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes","volume":"30","author":"Vaduganathan","year":"2024","journal-title":"Nat Med"},{"key":"2026080301192479700_ehag578-B148","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.124.069568","article-title":"Sodium-glucose cotransporter-2 inhibitors and Major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis","volume":"149","author":"Patel","year":"2024","journal-title":"Circulation"},{"key":"2026080301192479700_ehag578-B149","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/cvr\/cvac027","article-title":"Aldosterone and cardiovascular diseases","volume":"119","author":"Parksook","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2026080301192479700_ehag578-B150","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.kint.2019.02.030","article-title":"Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis","volume":"96","author":"Barrera-Chimal","year":"2019","journal-title":"Kidney Int"},{"key":"2026080301192479700_ehag578-B151","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/01.mnh.0000133976.32559.b0","article-title":"Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension","volume":"13","author":"Frey","year":"2004","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2026080301192479700_ehag578-B152","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/sj.ki.5000201","article-title":"Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury","volume":"69","author":"Ma","year":"2006","journal-title":"Kidney Int"},{"key":"2026080301192479700_ehag578-B153","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1161\/01.HYP.35.5.1078","article-title":"Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats","volume":"35","author":"Sun","year":"2000","journal-title":"Hypertension"},{"key":"2026080301192479700_ehag578-B154","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1093\/eurheartj\/ehac352","article-title":"Aldosterone in chronic kidney disease and renal outcomes","volume":"43","author":"Verma","year":"2022","journal-title":"Eur Heart J"},{"key":"2026080301192479700_ehag578-B155","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jcmg.2021.07.004","article-title":"Machine learning-derived echocardiographic phenotypes predict heart failure incidence in asymptomatic individuals","volume":"15","author":"Kobayashi","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026080301192479700_ehag578-B156","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1161\/CIRCULATIONAHA.116.024825","article-title":"Contemporary assessment of left ventricular diastolic function in older adults: the atherosclerosis risk in communities study","volume":"135","author":"Shah","year":"2017","journal-title":"Circulation"},{"key":"2026080301192479700_ehag578-B157","doi-asserted-by":"publisher","first-page":"H2372","DOI":"10.1152\/ajpheart.00283.2011","article-title":"A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone","volume":"301","author":"L\u00f3pez-Andr\u00e9s","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026080301192479700_ehag578-B158","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0008-6363(03)00534-0","article-title":"Induction of protein synthesis in cardiac fibroblasts by cardiotrophin-1: integration of multiple signaling pathways","volume":"60","author":"Freed","year":"2003","journal-title":"Cardiovasc Res"},{"key":"2026080301192479700_ehag578-B159","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1161\/HYPERTENSIONAHA.112.198986","article-title":"Aldosterone-specific activation of cardiomyocyte mineralocorticoid receptor in vivo","volume":"61","author":"Messaoudi","year":"2013","journal-title":"Hypertension"},{"key":"2026080301192479700_ehag578-B160","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jchf.2014.08.002","article-title":"The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries","volume":"3","author":"Calvier","year":"2015","journal-title":"JACC Heart Fail"},{"key":"2026080301192479700_ehag578-B161","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1161\/HYPERTENSIONAHA.115.06530","article-title":"Deoxycorticosterone acetate\/salt-induced cardiac but not renal injury is mediated by endothelial mineralocorticoid receptors independently from blood pressure","volume":"67","author":"Lother","year":"2016","journal-title":"Hypertension"},{"key":"2026080301192479700_ehag578-B162","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1161\/ATVBAHA.112.300569","article-title":"Galectin-3 mediates aldosterone-induced vascular fibrosis","volume":"33","author":"Calvier","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026080301192479700_ehag578-B163","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1161\/01.HYP.0000078357.92682.EC","article-title":"Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling","volume":"42","author":"Pu","year":"2003","journal-title":"Hypertension"},{"key":"2026080301192479700_ehag578-B164","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1161\/ATVBAHA.119.312954","article-title":"Endothelial mineralocorticoid receptors contribute to vascular inflammation in atherosclerosis in a sex-specific manner","volume":"39","author":"Moss","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026080301192479700_ehag578-B165","doi-asserted-by":"publisher","first-page":"3386","DOI":"10.1093\/cvr\/cvac007","article-title":"Smooth muscle mineralocorticoid receptor as an epigenetic regulator of vascular ageing","volume":"118","author":"Ibarrola","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2026080301192479700_ehag578-B166","doi-asserted-by":"publisher","first-page":"155165","DOI":"10.1016\/j.metabol.2022.155165","article-title":"Endothelial sodium channel activation mediates DOCA-salt-induced endothelial cell and arterial stiffening","volume":"130","author":"Zhang","year":"2022","journal-title":"Metabolism"},{"key":"2026080301192479700_ehag578-B167","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s10157-011-0498-x","article-title":"Aldosterone stimulates nuclear factor-kappa B activity and transcription of intercellular adhesion molecule-1 and connective tissue growth factor in rat mesangial cells via serum- and glucocorticoid-inducible protein kinase-1","volume":"16","author":"Terada","year":"2012","journal-title":"Clin Exp Nephrol"},{"key":"2026080301192479700_ehag578-B168","doi-asserted-by":"publisher","first-page":"191","DOI":"10.4049\/jimmunol.0802886","article-title":"Aldosterone promotes autoimmune damage by enhancing Th17-mediated immunity","volume":"184","author":"Herrada","year":"2010","journal-title":"J Immunol (Baltimore, Md: 1950)"},{"key":"2026080301192479700_ehag578-B169","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/jch.14117","article-title":"Confounders of the aldosterone-to-renin ratio when used as a screening test in hypertensive patients: a critical analysis of the literature","volume":"23","author":"Veldhuizen","year":"2021","journal-title":"J Clin Hypertens (Greenwich, Conn)"},{"key":"2026080301192479700_ehag578-B170","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1210\/clinem\/dgaf284","article-title":"Primary aldosteronism: an endocrine society clinical practice guideline","volume":"110","author":"Adler","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026080301192479700_ehag578-B171","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1161\/CIRCULATIONAHA.106.634626","article-title":"High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction","volume":"114","author":"Beygui","year":"2006","journal-title":"Circulation"},{"key":"2026080301192479700_ehag578-B172","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1093\/eurheartj\/ehn383","article-title":"Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction","volume":"29","author":"Palmer","year":"2008","journal-title":"Eur Heart J"},{"key":"2026080301192479700_ehag578-B173","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.ahj.2008.12.013","article-title":"Aldosterone and long-term outcome after myocardial infarction: a substudy of the French nationwide observatoire sur la prise en charge hospitali\u00e8re, l'Evolution \u00e0 un an et les caRact\u00e9ristiques de patients pr\u00e9sentant un infArctus du myocarde avec ou sans onde Q (OPERA) study","volume":"157","author":"Beygui","year":"2009","journal-title":"Am Heart J"},{"key":"2026080301192479700_ehag578-B174","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1093\/eurheartj\/ehr176","article-title":"Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure","volume":"33","author":"Ivanes","year":"2012","journal-title":"Eur Heart J"},{"key":"2026080301192479700_ehag578-B175","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1161\/HYPERTENSIONAHA.114.03311","article-title":"Serum aldosterone and death, end-stage renal disease, and cardiovascular events in blacks and whites: findings from the chronic renal insufficiency cohort (CRIC) study","volume":"64","author":"Deo","year":"2014","journal-title":"Hypertension"},{"key":"2026080301192479700_ehag578-B176","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1161\/01.CIR.82.5.1730","article-title":"Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS trial study group","volume":"82","author":"Swedberg","year":"1990","journal-title":"Circulation"},{"key":"2026080301192479700_ehag578-B177","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1053\/euhj.1998.1093","article-title":"Two-year time course and significance of neurohumoral activation in the survival and ventricular enlargement (SAVE) study","volume":"19","author":"Vantrimpont","year":"1998","journal-title":"Eur Heart J"},{"key":"2026080301192479700_ehag578-B178","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.ehj.2003.10.030","article-title":"The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT","volume":"25","author":"Latini","year":"2004","journal-title":"Eur Heart J"},{"key":"2026080301192479700_ehag578-B179","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1093\/eurheartj\/ehq019","article-title":"Plasma aldosterone levels are associated with increased cardiovascular mortality: the ludwigshafen risk and cardiovascular health (LURIC) study","volume":"31","author":"Tomaschitz","year":"2010","journal-title":"Eur Heart J"},{"key":"2026080301192479700_ehag578-B180","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1093\/eurjhf\/hft100","article-title":"Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial","volume":"15","author":"Girerd","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026080301192479700_ehag578-B181","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/eurheartj\/ehr292","article-title":"Serum aldosterone and its relationship to left ventricular structure and geometry in patients with preserved left ventricular ejection fraction","volume":"33","author":"Edelmann","year":"2012","journal-title":"Eur Heart J"},{"key":"2026080301192479700_ehag578-B182","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1161\/CIRCULATIONAHA.124.073507","article-title":"Subclinical primary aldosteronism and major adverse cardiovascular events: a longitudinal population-based cohort study","volume":"152","author":"Goupil","year":"2025","journal-title":"Circulation"},{"key":"2026080301192479700_ehag578-B183","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1136\/heartasia-2012-010129","article-title":"Aldosterone predicts major adverse cardiovascular events in patients with acute myocardial infarction","volume":"4","author":"Yuyun","year":"2012","journal-title":"Heart Asia"},{"key":"2026080301192479700_ehag578-B184","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1161\/HYPERTENSIONAHA.122.19134","article-title":"Cardiac structure and function across the spectrum of aldosteronism: the atherosclerosis risk in communities study","volume":"79","author":"Brown","year":"2022","journal-title":"Hypertension"},{"key":"2026080301192479700_ehag578-B185","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1161\/CIRCHEARTFAILURE.109.868513","article-title":"Serum cortisol as a useful predictor of cardiac events in patients with chronic heart failure: the impact of oxidative stress","volume":"2","author":"Yamaji","year":"2009","journal-title":"Circ Heart Fail"},{"key":"2026080301192479700_ehag578-B186","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.cardfail.2014.12.011","article-title":"Prognostic value of aldosterone and cortisol in patients hospitalized for acutely decompensated chronic heart failure with and without mineralocorticoid receptor antagonism","volume":"21","author":"G\u00fcder","year":"2015","journal-title":"J Card Fail"},{"key":"2026080301192479700_ehag578-B187","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1161\/CIRCULATIONAHA.106.653964","article-title":"Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure","volume":"115","author":"G\u00fcder","year":"2007","journal-title":"Circulation"},{"key":"2026080301192479700_ehag578-B188","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"394","author":"Agarwal","year":"2019","journal-title":"Lancet (London, England)"},{"key":"2026080301192479700_ehag578-B189","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026080301192479700_ehag578-B190","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2026080301192479700_ehag578-B191","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2026080301192479700_ehag578-B192","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"2026080301192479700_ehag578-B193","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone's antifibrotic activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension"},{"key":"2026080301192479700_ehag578-B194","doi-asserted-by":"publisher","first-page":"e0193380","DOI":"10.1371\/journal.pone.0193380","article-title":"Preclinical pharmacology of AZD9977: a novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion","volume":"13","author":"Bamberg","year":"2018","journal-title":"PLoS One"},{"key":"2026080301192479700_ehag578-B195","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/cts.12705","article-title":"Safety, tolerability, and pharmacokinetics of the mineralocorticoid receptor modulator AZD9977 in healthy men: a phase I multiple ascending dose study","volume":"13","author":"Whittaker","year":"2020","journal-title":"Clin Transl Sci"},{"key":"2026080301192479700_ehag578-B196","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1002\/ejhf.3294","article-title":"Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: results from the phase 2b MIRACLE trial","volume":"26","author":"Lam","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026080301192479700_ehag578-B197","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/bs.vh.2018.10.002","article-title":"Inhibitors of aldosterone synthase","volume":"109","author":"Weldon","year":"2019","journal-title":"Vitam Horm"},{"key":"2026080301192479700_ehag578-B198","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMoa2507109","article-title":"Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension","volume":"393","author":"Flack","year":"2025","journal-title":"N Engl J Med"},{"key":"2026080301192479700_ehag578-B199","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2501440","article-title":"Lorundrostat efficacy and safety in patients with uncontrolled hypertension","volume":"392","author":"Laffin","year":"2025","journal-title":"N Engl J Med"},{"key":"2026080301192479700_ehag578-B200","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"key":"2026080301192479700_ehag578-B201","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1001\/jama.2023.16029","article-title":"Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the target-HTN randomized clinical trial","volume":"330","author":"Laffin","year":"2023","journal-title":"JAMA"},{"key":"2026080301192479700_ehag578-B202","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet (London, England)"},{"key":"2026080301192479700_ehag578-B203","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/eurheartj\/ehaa758","article-title":"The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart \u2018OMics\u2019 in AGEing (HOMAGE) randomized clinical trial","volume":"42","author":"Cleland","year":"2021","journal-title":"Eur Heart J"},{"key":"2026080301192479700_ehag578-B204","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"key":"2026080301192479700_ehag578-B205","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/ejhf.2726","article-title":"Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials","volume":"25","author":"Ferreira","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026080301192479700_ehag578-B206","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1002\/ejhf.2579","article-title":"The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial","volume":"24","author":"Kobayashi","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026080301192479700_ehag578-B207","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/ejhf.2394","article-title":"Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial","volume":"24","author":"Ravassa","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026080301192479700_ehag578-B208","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ijcard.2023.01.088","article-title":"Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: pooled analysis of three randomized trials","volume":"377","author":"Ferreira","year":"2023","journal-title":"Int J Cardiol"},{"key":"2026080301192479700_ehag578-B209","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jchf.2020.11.010","article-title":"Proteomic and mechanistic analysis of spironolactone in patients at risk for HF","volume":"9","author":"Ferreira","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2026080301192479700_ehag578-B210","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2026080301192479700_ehag578-B211","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1093\/eurheartj\/ehu164","article-title":"Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the randomized double-blind reminder study","volume":"35","author":"Montalescot","year":"2014","journal-title":"Eur Heart J"},{"key":"2026080301192479700_ehag578-B212","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1016\/j.jacc.2016.02.033","article-title":"Early aldosterone blockade in acute myocardial infarction: the ALBATROSS randomized clinical trial","volume":"67","author":"Beygui","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026080301192479700_ehag578-B213","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1056\/NEJMoa2405923","article-title":"Routine spironolactone in acute myocardial infarction","volume":"392","author":"Jolly","year":"2025","journal-title":"N Engl J Med"},{"key":"2026080301192479700_ehag578-B214","doi-asserted-by":"publisher","first-page":"102531","DOI":"10.1016\/j.jchf.2025.102531","article-title":"Mineralocorticoid receptor antagonists in myocardial infarction patients: a systematic review and meta-analysis of randomized trials","volume":"13","author":"d'Entremont","year":"2025","journal-title":"JACC Heart Fail"},{"key":"2026080301192479700_ehag578-B215","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.1093\/eurheartj\/ehaf457","article-title":"Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fraction","volume":"46","author":"Kobayashi","year":"2025","journal-title":"Eur Heart J"},{"key":"2026080301192479700_ehag578-B216","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.jchf.2022.07.013","article-title":"Finerenone and heart failure outcomes by kidney function\/albuminuria in chronic kidney disease and diabetes","volume":"10","author":"Filippatos","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2026080301192479700_ehag578-B217","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.1038\/s41591-024-03263-5","article-title":"Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial","volume":"30","author":"Hobbs","year":"2024","journal-title":"Nat Med"},{"key":"2026080301192479700_ehag578-B218","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(25)01194-8","article-title":"Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis","volume":"406","author":"Rossignol","year":"2025","journal-title":"Lancet (London England)"},{"key":"2026080301192479700_ehag578-B219","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S0140-6736(25)01198-5","article-title":"Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial","volume":"406","author":"Walsh","year":"2025","journal-title":"Lancet (London, England)"},{"key":"2026080301192479700_ehag578-B220","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet (London England)"},{"key":"2026080301192479700_ehag578-B221","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1161\/HYPERTENSIONAHA.121.17073","article-title":"Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: results of the BLOCK-CKD study","volume":"78","author":"Bakris","year":"2021","journal-title":"Hypertension"},{"key":"2026080301192479700_ehag578-B222","author":"NORDISK N"},{"key":"2026080301192479700_ehag578-B223","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","article-title":"Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN study)","volume":"75","author":"Ito","year":"2020","journal-title":"Hypertension"},{"key":"2026080301192479700_ehag578-B224","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1093\/eurheartj\/ehaf225","article-title":"Aldosterone-targeted therapies: early implementation in resistant hypertension and chronic kidney disease","volume":"46","author":"Kobayashi","year":"2025","journal-title":"Eur Heart J"},{"key":"2026080301192479700_ehag578-B225","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1056\/NEJMc1612601","article-title":"Spironolactone metabolites in TOPCAT\u2014new insights into regional variation","volume":"376","author":"de Denus","year":"2017","journal-title":"N Engl J Med"},{"key":"2026080301192479700_ehag578-B226","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1002\/ejhf.621","article-title":"A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis","volume":"18","author":"Girerd","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026080301192479700_ehag578-B227","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1016\/j.jacc.2024.08.033","article-title":"Why have we not been able to demonstrate reduced mortality in patients with HFmrEF\/HFpEF?","volume":"84","author":"Kondo","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026080301192479700_ehag578-B228","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1001\/jamacardio.2025.0860","article-title":"Mode of death in patients with heart failure with mildly reduced or preserved ejection fraction: the FINEARTS-HF randomized clinical trial","volume":"10","author":"Desai","year":"2025","journal-title":"JAMA Cardiol"},{"key":"2026080301192479700_ehag578-B229","doi-asserted-by":"publisher","first-page":"102497","DOI":"10.1016\/j.jchf.2025.03.041","article-title":"Efficacy and safety of finerenone in heart failure with preserved ejection fraction: a FINE-HEART analysis","volume":"13","author":"Ostrominski","year":"2025","journal-title":"JACC Heart Fail"},{"key":"2026080301192479700_ehag578-B230","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"2026080301192479700_ehag578-B231","doi-asserted-by":"publisher","first-page":"e076444","DOI":"10.1136\/bmjopen-2023-076444","article-title":"Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials","volume":"14","author":"Bansal","year":"2024","journal-title":"BMJ open"},{"key":"2026080301192479700_ehag578-B232","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1111\/dom.15197","article-title":"The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: post hoc analysis of the FIDELITY study","volume":"25","author":"Rossing","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2026080301192479700_ehag578-B233","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/ehjcvp\/pvac054","article-title":"Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease","volume":"9","author":"Filippatos","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026080301192479700_ehag578-B234","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.kint.2022.08.040","article-title":"A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes","volume":"103","author":"Bakris","year":"2023","journal-title":"Kidney Int"},{"key":"2026080301192479700_ehag578-B235","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jchf.2019.08.019","article-title":"Influence of age on efficacy and safety of spironolactone in heart failure","volume":"7","author":"Vardeny","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026080301192479700_ehag578-B236","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jchf.2019.01.003","article-title":"Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial","volume":"7","author":"Merrill","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026080301192479700_ehag578-B237","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.amjcard.2021.01.018","article-title":"Effect of obesity on response to spironolactone in patients with heart failure with preserved ejection fraction","volume":"146","author":"Elkholey","year":"2021","journal-title":"Am J Cardiol"},{"key":"2026080301192479700_ehag578-B238","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.amjcard.2018.11.022","article-title":"Comparison of outcomes in patients with diabetes Mellitus treated with versus without insulin\u202f+\u202fheart failure with preserved left ventricular ejection fraction (from the TOPCAT study)","volume":"123","author":"Huynh","year":"2019","journal-title":"Am J Cardiol"},{"key":"2026080301192479700_ehag578-B239","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jchf.2018.05.005","article-title":"Atrial fibrillation in heart failure with preserved ejection fraction: the TOPCAT trial","volume":"6","author":"Cikes","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2026080301192479700_ehag578-B240","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jchf.2018.10.017","article-title":"Efficacy and safety of spironolactone in patients with HFpEF and chronic kidney disease","volume":"7","author":"Beldhuis","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026080301192479700_ehag578-B241","doi-asserted-by":"publisher","first-page":"e012437","DOI":"10.1161\/CIRCHEARTFAILURE.124.012437","article-title":"Finerenone improves outcomes in patients with heart failure with mildly reduced or preserved ejection fraction irrespective of age: a prespecified analysis of FINEARTS-HF","volume":"17","author":"Chimura","year":"2024","journal-title":"Circ Heart Fail"},{"key":"2026080301192479700_ehag578-B242","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1001\/jamacardio.2024.4613","article-title":"Finerenone in women and men with heart failure with mildly reduced or preserved ejection fraction: a secondary analysis of the FINEARTS-HF randomized clinical trial","volume":"10","author":"Chimura","year":"2025","journal-title":"JAMA Cardiol"},{"key":"2026080301192479700_ehag578-B243","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jacc.2024.10.111","article-title":"Finerenone, obesity, and heart failure with mildly reduced\/preserved ejection fraction: prespecified analysis of FINEARTS-HF","volume":"85","author":"Butt","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026080301192479700_ehag578-B244","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/ejhf.3649","article-title":"Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the FINEARTS-HF trial","volume":"27","author":"Butt","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026080301192479700_ehag578-B245","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1001\/jamacardio.2025.0848","article-title":"Finerenone and atrial fibrillation in heart failure: a secondary analysis of the FINEARTS-HF randomized clinical trial","volume":"10","author":"Matsumoto","year":"2025","journal-title":"JAMA Cardiol"},{"key":"2026080301192479700_ehag578-B246","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1002\/ejhf.3661","article-title":"Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the FINEARTS-HF trial","volume":"27","author":"Butt","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026080301192479700_ehag578-B247","doi-asserted-by":"publisher","first-page":"102778","DOI":"10.1016\/j.jchf.2025.102778","article-title":"Finerenone and cardiovascular outcomes according to baseline kidney function in patients with heart failure: the FINEARTS-HF trial","volume":"14","author":"Mc Causland","year":"2025","journal-title":"JACC Heart Fail"},{"key":"2026080301192479700_ehag578-B248","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.cardfail.2021.12.005","article-title":"The effect of spironolactone in patients with obesity at risk for heart failure: proteomic insights from the HOMAGE trial","volume":"28","author":"Verdonschot","year":"2022","journal-title":"J Card Fail"},{"key":"2026080301192479700_ehag578-B249","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1016\/j.jacc.2025.08.039","article-title":"Anthropometric measures, cardiovascular outcomes, and treatment effects of finerenone in cardiovascular-kidney-metabolic disease: pooled participant-level analysis of 3 global trials","volume":"86","author":"Ostrominski","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026080301192479700_ehag578-B250","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.cardfail.2022.01.012","article-title":"Rates of spironolactone initiation and subsequent hyperkalemia hospitalizations in patients with heart failure with preserved ejection fraction following the TOPCAT trial: a cohort study of Medicare beneficiaries","volume":"28","author":"Desai","year":"2022","journal-title":"J Card Fail"},{"key":"2026080301192479700_ehag578-B251","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1016\/j.jacc.2020.04.021","article-title":"Abnormalities of potassium in heart failure: JACC state-of-the-art review","volume":"75","author":"Ferreira","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026080301192479700_ehag578-B252","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736(24)01733-1","article-title":"Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis","volume":"404","author":"Jhund","year":"2024","journal-title":"Lancet (London, England)"},{"key":"2026080301192479700_ehag578-B253","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/ckj\/sfac234","article-title":"A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease","volume":"16","author":"Agarwal","year":"2023","journal-title":"Clin Kidney J"},{"key":"2026080301192479700_ehag578-B254","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13413","article-title":"Efficacy and safety of mineralocorticoid receptor antagonists with ACEI\/ARB treatment for diabetic nephropathy: a meta-analysis","author":"Zuo","year":"2019","journal-title":"Int J Clin Pract"},{"key":"2026080301192479700_ehag578-B255","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"2026080301192479700_ehag578-B256","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"key":"2026080301192479700_ehag578-B257","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.cardfail.2018.03.002","article-title":"Incident hyperkalemia, hypokalemia, and clinical outcomes during spironolactone treatment of heart failure with preserved ejection fraction: analysis of the TOPCAT trial","volume":"24","author":"Desai","year":"2018","journal-title":"J Card Fail"},{"key":"2026080301192479700_ehag578-B258","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1001\/jamacardio.2024.4539","article-title":"Finerenone, serum potassium, and clinical outcomes in heart failure with mildly reduced or preserved ejection fraction","volume":"10","author":"Vardeny","year":"2025","journal-title":"JAMA Cardiol"},{"key":"2026080301192479700_ehag578-B259","doi-asserted-by":"publisher","first-page":"102479","DOI":"10.1016\/j.jchf.2025.02.025","article-title":"Interaction between aldosterone and mineralocorticoid receptor antagonist: findings from the EPHESUS trial","volume":"13","author":"Kobayashi","year":"2025","journal-title":"JACC Heart Fail"},{"key":"2026080301192479700_ehag578-B260","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1002\/ejhf.70052","article-title":"Interplay of serum potassium and kidney function with finerenone in heart failure with mildly reduced or preserved ejection fraction: findings from FINEARTS-HF","volume":"27","author":"Ferreira","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026080301192479700_ehag578-B261","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1093\/eurheartj\/ehad389","article-title":"Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction","volume":"44","author":"Pandey","year":"2023","journal-title":"Eur Heart J"},{"key":"2026080301192479700_ehag578-B262","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.jacc.2022.01.029","article-title":"Mineralocorticoid receptor antagonists and empagliflozin in patients with heart failure and preserved ejection fraction","volume":"79","author":"Ferreira","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026080301192479700_ehag578-B263","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1002\/ejhf.2722","article-title":"Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril\/valsartan","volume":"24","author":"Yang","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026080301192479700_ehag578-B264","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1161\/CIRCULATIONAHA.124.072055","article-title":"Effects of the nonsteroidal MRA finerenone with and without concomitant SGLT2 inhibitor use in heart failure","volume":"151","author":"Vaduganathan","year":"2025","journal-title":"Circulation"},{"key":"2026080301192479700_ehag578-B265","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.2337\/dc22-0294","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis","volume":"45","author":"Rossing","year":"2022","journal-title":"Diabetes Care"},{"key":"2026080301192479700_ehag578-B266","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials","volume":"145","author":"Neuen","year":"2022","journal-title":"Circulation"},{"key":"2026080301192479700_ehag578-B267","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1093\/eurheartj\/ehac306","article-title":"Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-pooled","volume":"43","author":"Ferreira","year":"2022","journal-title":"Eur Heart J"},{"key":"2026080301192479700_ehag578-B268","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.jacc.2025.05.033","article-title":"Sodium-glucose cotransporter 2 inhibitor with and without an aldosterone antagonist for heart failure with preserved ejection fraction: the SOGALDI-PEF trial","volume":"86","author":"Ferreira","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026080301192479700_ehag578-B269","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med"},{"key":"2026080301192479700_ehag578-B270","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3109\/10641963.2014.987391","article-title":"Comparison of aldosterone synthesis in adrenal cells, effect of various AT1 receptor blockers with or without atrial natriuretic peptide","volume":"37","author":"Miura","year":"2015","journal-title":"Clin Exp Hypertens"},{"key":"2026080301192479700_ehag578-B271","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.jacc.2018.11.042","article-title":"Effects of sacubitril\/valsartan on biomarkers of extracellular matrix regulation in patients with HFrEF","volume":"73","author":"Zile","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026080301192479700_ehag578-B272","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jchf.2020.08.014","article-title":"Cardiovascular and renal outcomes of mineralocorticoid receptor antagonist use in PARAGON-HF","volume":"9","author":"Jering","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2026080301192479700_ehag578-B273","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1161\/CIRCULATIONAHA.123.066314","article-title":"Aldosterone synthase inhibitors and mineralocorticoid receptor antagonists: competitors or collaborators?","volume":"149","author":"Pitt","year":"2024","journal-title":"Circulation"},{"key":"2026080301192479700_ehag578-B274"},{"key":"2026080301192479700_ehag578-B275","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1002\/ejhf.3453","article-title":"The spironolactone initiation registry randomized interventional trial in heart failure with preserved ejection fraction (SPIRRIT-HFpEF): rationale and design","volume":"26","author":"Lund","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026080301192479700_ehag578-B276","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1002\/ejhf.2859","article-title":"A machine learning-derived echocardiographic algorithm identifies people at risk of heart failure with distinct cardiac structure, function, and response to spironolactone: findings from the HOMAGE trial","volume":"25","author":"Kobayashi","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026080301192479700_ehag578-B277","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S2213-8587(18)30071-8","article-title":"Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies","volume":"6","author":"Williams","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026080301192479700_ehag578-B278","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/ehjcvp\/pvab031","article-title":"Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial","volume":"8","author":"Ferreira","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026080301192479700_ehag578-B279","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2026.103111","article-title":"Renin, aldosterone, and treatment response to dapagliflozin, spironolactone, and their combination: an analysis from SOGALDI-PEF","author":"Ferreira","year":"2026","journal-title":"JACC Heart Fail"},{"key":"2026080301192479700_ehag578-B280","doi-asserted-by":"publisher","first-page":"102452","DOI":"10.1016\/j.jchf.2025.02.021","article-title":"Mineralocorticoid receptor antagonist use in hypertension to prevent heart failure","volume":"13","author":"Pitt","year":"2025","journal-title":"JACC Heart Fail"},{"key":"2026080301192479700_ehag578-B281","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jacc.2025.05.038","article-title":"Blinded withdrawal of finerenone after long-term treatment in the FINEARTS-HF trial","volume":"86","author":"Vaduganathan","year":"2025","journal-title":"J Am Coll Cardiol"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehag578\/70454253\/ehag578.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehag578\/70454253\/ehag578.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T05:19:35Z","timestamp":1785734375000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article\/doi\/10.1093\/eurheartj\/ehag578\/8749110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":281,"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehag578","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"article-number":"ehag578"}}